{{Rsnum
|rsid=8180115
|Gene=STX18
|Chromosome=4
|position=4520188
|Orientation=plus
|GMAF=0.2291
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=STX18
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 5.3 | 31.0 | 63.7
| HCB | 7.4 | 48.1 | 44.4
| JPT | 8.0 | 41.1 | 50.9
| YRI | 9.5 | 34.7 | 55.8
| ASW | 1.8 | 22.8 | 75.4
| CHB | 7.4 | 48.1 | 44.4
| CHD | 19.3 | 46.8 | 33.9
| GIH | 18.0 | 48.0 | 34.0
| LWK | 3.6 | 48.2 | 48.2
| MEX | 8.6 | 29.3 | 62.1
| MKK | 8.3 | 39.1 | 52.6
| TSI | 1.0 | 29.7 | 69.3
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs8180115
|Name_s=
|Gene_s=STX18
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 89. Study population/ethnicity: 89 Yorubans. Significance metric(s): p = 0.00005. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109520
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs8180115
|overall_frequency_n=32
|overall_frequency_d=126
|overall_frequency=0.253968
|n_genomes=21
|n_genomes_annotated=0
|n_haplomes=25
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}